<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03869502</url>
  </required_header>
  <id_info>
    <org_study_id>BlastCrisis</org_study_id>
    <nct_id>NCT03869502</nct_id>
  </id_info>
  <brief_title>European CML Blast Crisis Register</brief_title>
  <acronym>BlastCrisis</acronym>
  <official_title>European CML Blast Crisis Register</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Annamaria Brioli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentric prospective and retrospective register collecting patient with CML blast crisis
      diagnosed in Germany and Europe
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since the advent of treatment with tyrosine kinase inhibitors (TKI), the incidence of blast
      crises has significantly decreased. Nevertheless, about 5% of patients diagnosed with chronic
      myeloid leukemia (CML) will evolve into a blast phase at some point during the course of
      their disease. Furthermore, despite the advances made in CML treatment, outcome of patients
      with blast crises are still dismal. Due to the rarity of this condition clinical trials are
      challenging, and collaboration between researchers both at national and international level
      is needed to collect a meaningful number of data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>through study completion in 2024</time_frame>
    <description>how many patients survive after a blast crisis event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of hematologic response to treatment</measure>
    <time_frame>through study completion in 2024</time_frame>
    <description>how many patients have a hematologic response to the local standard Treatment after a blast crisis event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of molecular response to treatment</measure>
    <time_frame>through study completion in 2024</time_frame>
    <description>how many patients have a molecular response to the local standard Treatment after a blast crisis event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of blast crises in Europe in the era of TKI treatment</measure>
    <time_frame>through study completion in 2024</time_frame>
    <description>how many patients have blast crisis events compared to all treated CML-patients in the trial centers</description>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Chronic Myeloid Leukemia in Myeloid Blast Crisis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with CML Blast crisis, either newly diagnosed or as evolution of a CML in chronic
        phase
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Diagnosis of BCR‐ABL positive CML blast crisis according to the WHO criteria:

               -  Blasts 20% or more of peripheral blood white cells or bone marrow cells or

               -  Extramedullary blast proliferation or

               -  Large foci or clusters of blasts in bone marrow biopsy

        Exclusion Criteria:

          -  Lack of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annamaria Brioli, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univerity of Jena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annamaria Brioli, PhD MD</last_name>
    <phone>+49 36419324576</phone>
    <email>blastcrisis@med.uni-jena.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Fabisch, Dr.</last_name>
    <phone>+49 36419396670</phone>
    <email>blastcrisis@med.uni-jena.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Masaryk University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiri Mayer, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Röllig, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim R. Göthert, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annamaria Brioli, PhD MD</last_name>
      <phone>+49 36419324576</phone>
      <email>blastcrisis@med.uni-jena.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AöR</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg-Nikolaus Franke, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68169</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Saussele, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Muenster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Stelljes, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>I. P. Pavlov First St. Petersburg State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Morozova, PhD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Research Center for Radiation Medicine</name>
      <address>
        <city>Kiev</city>
        <zip>02000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iryna Dyagil, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Jena</investigator_affiliation>
    <investigator_full_name>Annamaria Brioli</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>A joint publication is planned. But no data of trial Centers will be shared with the other trial centers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

